查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924660

恩夫韋地注射市場按患者類別、治療線、劑型、給藥途徑和年齡層分類 - 全球預測 2026-2032

Enfuvirtide for Injection Market by Patient Category, Therapy Line, Dosage Form, Administration Setting, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，恩夫韋地注射劑市場價值將達到 3.3851 億美元，到 2026 年將成長至 3.6997 億美元，到 2032 年將達到 6.3801 億美元，複合年成長率為 9.47%。

關鍵市場統計數據
基準年 2025 3.3851億美元
預計年份：2026年 3.6997億美元
預測年份 2032 6.3801億美元
複合年成長率 (%) 9.47%

本書精闢地介紹了注射用恩夫韋地在現代愛滋病治療中的臨床定位、操作複雜性以及相關人員的考量因素。

恩夫韋地是一種合成胜肽類抗逆轉錄病毒藥物，主要透過注射給藥，適用於對常規治療方法產生抗藥性的患者。其治療特性、劑量複雜性和給藥途徑均與口服抗逆轉錄病毒不同，這影響臨床醫師、藥師和醫療系統將其納入治療方案的方式。由於恩夫韋地是一種融合抑制劑，因此當需要一種作用機制不同的藥物來最佳化治療方案時，通常會考慮使用恩夫韋地。醫療專業人員會根據抗藥性模式、依從性以及注射耐受性等因素來評估其適用性。

臨床實踐、供應鏈物流和患者治療模式的重大變革正在重新定義注射型抗逆轉錄病毒藥物的應用和治療路徑。

注射型抗逆轉錄病毒藥物領域正經歷顯著的變革，這主要得益於臨床創新、給藥方式創新以及患者期望的不斷變化。製劑科學的進步和給藥裝置的改進降低了給藥難度，並擴大了注射療法的應用範圍。同時，嚴格的抗藥性檢測的廣泛應用以及更完善的治療流程的建立，也為恩夫韋地等藥物開闢了新的臨床應用領域，使其能夠為因抗藥性或不耐受而導致口服治療選擇有限的患者提供額外的價值。

近期貿易政策調整與關稅相關壓力如何推動注射劑治療藥物的供應鏈重組、籌資策略與韌性規劃

美國近期關稅政策的變化增加了注射用生物製藥和胜肽類藥物供應鏈計算的複雜性，影響了生產商和經銷商的籌資策略和成本結構。針對活性藥物成分、輔料和包裝材料的關稅提高了到岸成本，迫使生產商重新評估其採購基礎，並優先選擇貿易條件更有利地區的供應商。這一趨勢正在推動近岸外包和供應來源多元化，以降低關稅波動帶來的風險，並確保關鍵注射療法的持續供應。

詳細的細分分析闡明了通路、患者特徵、劑型和給藥環境等因素，這些因素將影響恩氟韋地肽的策略發展。

細分市場洞察對於了解恩夫韋地在不同供應管道和患者群體中的應用至關重要。詳細分析揭示了推動藥物推廣和取得的不同關鍵因素。考慮到分銷管道的動態變化，診所、醫院和零售藥局各自擁有不同的營運實踐和決策標準。診所分為綜合診所和專科診所，其注射劑支持和患者教育資源水平各不相同。醫院包括私立和公立機構，採購週期和預算框架也存在差異。零售藥局分為連鎖店和獨立藥局，其庫存管理能力和醫護人員協作能力也存在差異。這些差異為確定注射劑治療的起始、維持和患者追蹤的最佳環境提供了重要資訊。

美洲、歐洲、中東和非洲以及亞太地區在醫療服務取得、報銷、監管路徑和交付生態系統現狀方面的區域觀點

區域趨勢對注射型抗逆轉錄病毒的可及性、報銷框架、監管路徑和臨床實踐模式均有顯著影響。在美洲，醫療服務體系的特徵是公共計畫和私人支付者的多元化組合，這影響著採購週期和臨床醫生的獎勵。價格談判機制、報銷核准以及專科診所的可用性都會影響注射療法的引入和持續使用。為了應對與注射療法相關的依從性挑戰，美洲的相關人員通常致力於將其與現有的門診醫療基礎設施整合，並制定患者支持計劃。

從企業層面策略觀點探討注射療法的製造合作、交付創新、臨床證據舉措和生命週期管理方法。

公司層面的發展趨勢反映了臨床控制、生產規模和策略聯盟之間的平衡。擁有成熟產品系列的創新公司具備深厚的臨床數據、豐富的監管經驗以及與醫療保健網路的緊密聯繫，從而能夠開展有針對性的教育活動和處方集；而中型製造商和專業公司則能夠在包裝創新、替代劑型以及靈活的供應安排方面展現出靈活性，以適應分散式醫療保健環境。在整個競爭格局中，臨床研究團隊、契約製造和分銷專家之間的夥伴關係對於最佳化生產效率以及確保注射用肽類藥物符合低溫運輸和無菌要求至關重要。

為製造商、醫療保健系統和支付方提供實用建議，以協調證據、商業策略和供應鏈韌性，從而支持注射型抗逆轉錄病毒的推廣應用。

產業領導者應優先考慮整合臨床證據產生、營運準備和支付方合作。首先，應投資於臨床試驗和真實世界研究，以驗證特定潛在獲益亞群（例如具有單一藥物或多重抗藥性特徵的既往治療患者）的治療效果，並確保研究設計能夠涵蓋依從性和給藥相關終點。其次，應最佳化產品劑型和包裝，以方便在門診和居家照護環境中使用。這包括提供看護者培訓模組和標準化的低溫運輸管理通訊協定。

一份詳盡的調查方法，闡述了資料來源、訪談架構、三角驗證過程以及支撐分析的品管措施。

本研究採用多面向研究方法，結合了二手文獻綜述、相關人員諮詢和迭代檢驗，以確保分析的嚴謹性。二手文獻包括同儕審查的臨床文獻、監管申報文件和治療指南，用於建立臨床背景並驗證作用機制、劑量特徵和安全性考慮因素。一手研究包括對臨床醫生、藥屋主任、採購負責人和供應鏈專業人員進行結構化檢驗，以深入了解實際操作限制、劑量偏好和給藥環境。

綜合分析總結表明，需要協調臨床證據、營運準備和支付方參與，才能有效實現注射療法的可及性。

總之，我們強調，將臨床效益與營運效用和支付方的認知相結合，對於恩夫韋地等注射劑的成功引入至關重要。抗藥性管理和基於作用機制的臨床差異化必須與滿足培訓需求、劑型偏好以及貫穿整個醫療服務鏈的給藥環境的物流解決方案相協調。此外，供應鏈韌性與當地法規環境之間的策略互動將決定不同醫療體系中推廣應用的速度和永續性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依病患類別分類的恩夫韋地注射液市場

  • 接受過治療的患者
    • 單藥抗藥性
    • 多重抗藥性
  • 未治療的患者

9. 恩夫韋地注射液市場（依治療系列分類）

  • 後期治療
  • 二線治療
  • 三線治療

第10章 恩夫韋地注射液市場（以劑型分類）

  • 預填充式注射器
  • 管瓶

第11章 恩夫韋地注射液市場（依給藥途徑分類）

  • 住院病人
  • 門診病人

第12章 依年齡層別分類的恩夫韋地注射液市場

  • 成人
  • 兒童

第13章 恩夫韋地注射液市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 恩夫韋地注射液市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國恩夫韋地注射液市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國恩夫韋地注射液市場

第17章：中國恩夫韋地注射液市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AmbioPharm, Inc.
  • Chengdu Shengnuo Biopharm Co., Ltd
  • CordenPharma International GmbH
  • Didu Group Co., Ltd.
  • Genentech, Inc.
  • Hangzhou Go Top Peptide Biotech Co., Ltd.
  • JYMed Technology Co., Ltd.
  • NJPeptide, Inc.
  • Roche Holding AG
  • Trimeris
  • ZPC Biotechnology Co., Ltd.
Product Code: MRR-7A380DA7C409

The Enfuvirtide for Injection Market was valued at USD 338.51 million in 2025 and is projected to grow to USD 369.97 million in 2026, with a CAGR of 9.47%, reaching USD 638.01 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 338.51 million
Estimated Year [2026] USD 369.97 million
Forecast Year [2032] USD 638.01 million
CAGR (%) 9.47%

An incisive introduction to the clinical positioning operational complexities and stakeholder considerations shaping the use of injectable enfuvirtide in contemporary HIV care

Enfuvirtide is a synthetic peptide antiretroviral administered by injection, positioned predominantly for patients who have encountered resistance to conventional regimens. The therapeutic profile, dosing complexity, and administration route distinguish it from oral antiretroviral agents and shape how clinicians, pharmacists, and healthcare systems incorporate it into treatment pathways. Given its role as a fusion inhibitor, enfuvirtide is often considered when regimen optimization requires agents with a distinct mechanism of action, and practitioners evaluate its suitability within the context of resistance patterns, adherence considerations, and injection-related tolerability.

Clinical adoption of enfuvirtide is influenced by a range of practical factors that extend beyond efficacy alone. Injection training, cold chain logistics, and choices between prefilled syringes or vials are operational determinants that affect clinician preference and patient acceptance. Moreover, the drug's positioning within therapy lines and its utility for treatment-experienced patients with specific resistance profiles create a clinical niche that necessitates targeted educational outreach and clear guidelines. As a result, stakeholders across care settings must align on protocols for initiation, monitoring, and patient support to realize therapeutic benefit while minimizing barriers to use.

Key transformative shifts in clinical practice supply chain logistics and patient delivery models that are redefining injectable antiretroviral adoption and care pathways

The landscape for injectable antiretrovirals has undergone meaningful shifts driven by clinical innovation, delivery innovations, and evolving patient expectations. Advances in formulation science and improvements in delivery devices have reduced administration friction and expanded the contexts in which injectable therapies can be offered. Concurrently, the rise of precision resistance testing and more nuanced treatment algorithms has clarified the clinical niches where agents such as enfuvirtide deliver incremental value, particularly for patients with limited oral options due to resistance or intolerance.

Operational shifts are equally consequential. Health systems have reconfigured outpatient services and home care pathways to accommodate injectable therapies, integrating nurse-led programs, patient training modules, and remote adherence monitoring. Commercial dynamics have adjusted to this new paradigm as manufacturers and distributors refine packaging formats and supply logistics to better support clinics, hospitals, and home-based administration. As a result, the cumulative effect is a more flexible adoption environment where clinical utility, ease of administration, and integrated care models interact to reshape how injectable antiretrovirals are deployed.

How recent trade policy adjustments and tariff-related pressures are catalyzing supply chain redesign procurement strategies and resilience planning for injectable therapeutics

Recent tariff activity in the United States has added complexity to the supply chain calculus for injectable biologics and peptide therapeutics, affecting procurement strategies and cost structures for manufacturers and distributors. Tariff measures that target active pharmaceutical ingredients, excipients, or packaging components can increase landed costs, prompting manufacturers to reassess sourcing footprints and to prioritize suppliers in jurisdictions with more favorable trade terms. In turn, this dynamic encourages nearshoring and diversification of supply to mitigate exposure to tariff volatility and to preserve continuity of supply for critical injectable therapies.

Healthcare providers and procurement teams have responded by increasing emphasis on contractual flexibility and by seeking longer-term supply agreements that hedge against abrupt cost shifts. Payers and hospital systems are scrutinizing total cost of care implications, including the downstream effects of administration setting changes and the potential need for additional support services when therapy affordability is affected. Additionally, regulatory and customs processes have become more salient as logistics teams prioritize compliance and documentation to avoid clearance delays. Overall, tariffs are acting as a catalyst for strategic supply chain redesign rather than as an isolated cost pressure, accelerating a shift toward more resilient sourcing, enhanced inventory governance, and closer collaboration between manufacturers and downstream partners.

Deep segmentation insights explaining how distribution channels patient profiles dosage formats and administration settings influence the strategic deployment of enfuvirtide

Segmentation-driven insight is central to understanding how enfuvirtide will be utilized across delivery channels and patient cohorts, and a granular view reveals differentiated levers for adoption and access. When distribution channel dynamics are considered, clinics, hospitals, and retail pharmacies each present distinct operational realities and decision criteria; clinics span general and specialty clinics with varying levels of injection support and patient education resources, hospitals include private and public institutions with divergent procurement cycles and budgetary frameworks, and retail pharmacies encompass chain and independent outlets that differ in their capacity to manage storage and clinician coordination. These differences inform which settings are best suited for initiation, maintenance, and patient follow-up for an injectable agent.

Patient category segmentation highlights the clinical imperative: treatment experienced and treatment naive populations present different therapeutic rationales, with treatment experienced patients further characterized by mono-resistant and multi-drug resistant profiles, which directly influence regimen selection and the perceived value of a fusion inhibitor. Age group segmentation underscores both clinical and adherence considerations, as adult and pediatric cohorts have distinct dosing, counseling, and support needs; adults are further segmented into general adult and senior populations where comorbidity burden and polypharmacy matter, while pediatric patients encompass adolescent, child, and neonatal subgroups that require tailored administration approaches and caregiver support. Therapy line segmentation clarifies placement across later line, second line, and third line use, and the later line classification subdivides into fourth line and fifth line and beyond scenarios where clinical necessity and limited alternatives drive usage. Dosage form and administration setting complete the picture: prefilled syringes versus vials, including 180 mg and 90 mg vial formats, and inpatient versus outpatient administration settings, with inpatient care spanning general ward and intensive care unit contexts and outpatient care covering ambulatory clinics and home care, all shape logistics, training needs, and patient experience. Integrating these segmentation lenses allows stakeholders to identify high-priority use cases, tailor educational programs, and design distribution strategies that align with the operational capacities and clinical requirements of each segment.

Regional perspectives on access reimbursement regulatory pathways and delivery ecosystem realities across the Americas Europe Middle East Africa and Asia-Pacific

Regional dynamics exert a pronounced influence on access, reimbursement frameworks, regulatory pathways, and clinical practice patterns for injectable antiretrovirals. In the Americas, healthcare delivery is characterized by a diverse mix of public programs and private payers, which shapes procurement cycles and clinician incentives; pricing negotiation mechanisms, reimbursement approvals, and the presence of specialized clinics drive how injectable therapies are introduced and sustained. Stakeholders in the Americas frequently focus on integration with established outpatient infrastructure and the development of patient support programs to address adherence challenges associated with injection therapies.

In Europe, Middle East & Africa, heterogeneity across national health systems influences adoption timelines and the complexity of regulatory approvals, with some markets emphasizing centralized procurement and others operating through decentralized hospital budgets; this creates varying pathways for formulary inclusion and clinician adoption. Capacity constraints in certain regions necessitate tailored training and creative delivery models, including expansion of ambulatory care and task shifting to allied health personnel where appropriate. The Asia-Pacific region exhibits a wide spectrum of public and private healthcare arrangements, regulatory environments, and manufacturing capabilities. Robust domestic pharmaceutical manufacturing in several countries supports regional supply resilience, while disparities in healthcare infrastructure mean that home-based care and ambulatory clinic networks can be pivotal in enabling access. Across regions, cross-border trade dynamics, intellectual property frameworks, and local clinical guidelines shape how injectable antiretrovirals are evaluated and adopted, requiring manufacturers and providers to pursue regionally nuanced strategies that reflect local payer priorities, clinician workflows, and patient support needs.

Strategic company level perspectives on manufacturing collaborations delivery innovations clinical evidence initiatives and lifecycle management approaches for injectable therapies

Company-level dynamics reflect a balance between clinical stewardship, manufacturing scale, and strategic collaboration. Innovator organizations with established portfolios bring depth in clinical data, regulatory experience, and relationships with care networks, enabling targeted education and formulary engagement. At the same time, mid-sized manufacturers and specialty firms can provide agility in packaging innovation, alternate dosage forms, and flexible supply arrangements that appeal to decentralized care settings. Across the competitive landscape, partnerships between clinical research groups, contract manufacturing organizations, and distribution specialists are instrumental in optimizing production throughput and ensuring compliance with cold chain and sterility requirements for injectable peptides.

Intellectual property and lifecycle management strategies influence investment in next-generation delivery technologies, such as improved syringe designs and alternative vial configurations that simplify administration and reduce wastage. Companies are also investing in real-world evidence initiatives to demonstrate practical benefits in adherence and resistance management, and they are exploring collaborations with healthcare systems to pilot clinic-based and home-administration programs. These corporate actions are central to differentiating offerings and to building the trust required for clinicians and payers to incorporate an injectable agent into complex treatment regimens.

Actionable recommendations for manufacturers healthcare systems and payers to align evidence commercial strategy and supply chain resilience in support of injectable antiretroviral adoption

Industry leaders should prioritize integrated approaches that align clinical evidence generation with operational readiness and payer engagement. First, invest in clinical and real-world studies that document outcomes for the specific subgroups most likely to benefit, including treatment experienced patients with mono-resistant and multi-drug resistant profiles, and ensure that study designs capture adherence and administration-related endpoints. Second, optimize product formats and packaging to support ease of use in both ambulatory and home-care environments, including training modules for caregivers and standardized protocols for cold chain management.

Third, proactively engage payers and hospital procurement teams to clarify the clinical value proposition and to co-design pathways that minimize administrative friction at initiation. Fourth, reconfigure supply chains to enhance resilience against tariff and trade disruptions by diversifying component sourcing and considering selective nearshoring for critical inputs. Fifth, foster partnerships with nursing networks and specialty clinics to scale injection training and patient support services, thereby reducing barriers at the point of care. By executing on these priorities, companies and healthcare organizations can accelerate clinically appropriate adoption while aligning operational capabilities with patient needs.

Comprehensive research methodology detailing data sources interview frameworks triangulation processes and quality control measures underpinning the analysis

The study relies on a multi-method research approach that combines secondary literature review with stakeholder consultations and iterative validation to ensure analytical rigor. Secondary sources included peer-reviewed clinical literature, regulatory filings, and treatment guidelines to establish the clinical context and to verify mechanism of action, dosing characteristics, and safety considerations. Primary research involved structured interviews with clinicians, pharmacy directors, procurement officers, and supply chain specialists to capture real-world operational constraints, preferences for dosage forms, and views on administration settings.

Data triangulation was performed by cross-referencing interview findings with published clinical guidance and product labeling, and by validating logistical observations against distribution and cold chain best practices. Limitations were acknowledged, including variability in regional practice patterns and the evolving nature of resistance testing and treatment algorithms. To mitigate these, sensitivity checks were applied and methodological assumptions were documented to maintain transparency. Quality control included expert review panels and internal consistency checks to ensure that conclusions reflect robust synthesis rather than isolated perspectives.

Concluding synthesis emphasizing the necessity of aligning clinical evidence operational readiness and payer engagement to enable effective access for injectable therapeutics

The concluding synthesis highlights that successful deployment of an injectable agent such as enfuvirtide depends on aligning clinical utility with operational practicability and payer recognition. Clinical differentiation rooted in resistance management and mechanism of action must be matched by logistical solutions that address training needs, dosage format preferences, and administration settings across care continua. Moreover, the strategic interplay between supply chain resilience and regional regulatory environments will determine the speed and sustainability of adoption across diverse healthcare systems.

Ultimately, stakeholders that integrate targeted evidence generation, adaptable packaging and delivery models, and collaborative payer engagement are best positioned to overcome the unique challenges associated with injectable therapies. This holistic approach ensures that clinical value is accessible in the settings where it is most needed while maintaining the operational agility required to respond to trade and procurement dynamics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enfuvirtide for Injection Market, by Patient Category

  • 8.1. Treatment Experienced
    • 8.1.1. Mono-Resistant
    • 8.1.2. Multi-Drug Resistant
  • 8.2. Treatment Naive

9. Enfuvirtide for Injection Market, by Therapy Line

  • 9.1. Later Line
  • 9.2. Second Line
  • 9.3. Third Line

10. Enfuvirtide for Injection Market, by Dosage Form

  • 10.1. Prefilled Syringes
  • 10.2. Vials

11. Enfuvirtide for Injection Market, by Administration Setting

  • 11.1. Inpatient
  • 11.2. Outpatient

12. Enfuvirtide for Injection Market, by Age Group

  • 12.1. Adult
  • 12.2. Pediatric

13. Enfuvirtide for Injection Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Enfuvirtide for Injection Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Enfuvirtide for Injection Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Enfuvirtide for Injection Market

17. China Enfuvirtide for Injection Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AmbioPharm, Inc.
  • 18.6. Chengdu Shengnuo Biopharm Co., Ltd
  • 18.7. CordenPharma International GmbH
  • 18.8. Didu Group Co., Ltd.
  • 18.9. Genentech, Inc.
  • 18.10. Hangzhou Go Top Peptide Biotech Co., Ltd.
  • 18.11. JYMed Technology Co., Ltd.
  • 18.12. NJPeptide, Inc.
  • 18.13. Roche Holding AG
  • 18.14. Trimeris
  • 18.15. ZPC Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MONO-RESISTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MONO-RESISTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MONO-RESISTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MULTI-DRUG RESISTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MULTI-DRUG RESISTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MULTI-DRUG RESISTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT NAIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT NAIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT NAIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 114. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 135. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)